| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
REPORT |
First Department of Propaedeutic Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece
Correspondence to:
Correspondence to:
Dr P P Sfikakis, 3 Amaryllidos Str, 154 52, Athens, Greece;
psfikakis{at}med.uoa.gr
ABSTRACT
Behçet’s disease is a multisystemic, chronic relapsing inflammatory disease classified among the vasculitides. Recurrent mucocutaneous lesions may be the only symptoms in mild cases, but articular, ocular, vascular, and/or gastrointestinal and central nervous system involvement may occur in most of the patients. Ocular disease is the most frequent cause of morbidity leading to blindness in 25% of those affected. The various non-specific immunosuppressive drugs, used either alone or in combinations, frequently fail to control inflammation or maintain remissions. The aetiology of Behçet’s disease is unknown, however it is currently thought that a central pathogenetic role of tumour necrosis factor (TNF) in the inflammatory process is possible. Until June 2002, and according to published and anecdotal data, more than 80 patients from 10 different countries have received anti-TNF treatment.
The short-term effects of the anti-TNF monoclonal antibody infliximab have been reported in several case reports and small case series, whereas the effects of etanercept have been presented in recent conferences. Preliminary results strongly suggest that infliximab is remarkably effective in inducing short-term remission of almost all manifestations of the disease, including acute, sight threatening panuveitis. A double blind, placebo controlled, one month study on the efficacy of etanercept in suppressing the mucocutaneous manifestations of the disease showed beneficial results.
To date, significant side effects have not been reported. It seems that TNF block is an effective new treatment for patients with Behçet’s disease. Whether such treatment is superior to the conventional therapeutic approaches in preventing relapses and progression of the disease remains to be determined by carefully controlled studies. At least three open, long term studies, including larger numbers of patients are currently being conducted.
Keywords: Behçet’s disease; tumour necrosis factor
This article has been cited by other articles:
|
|
 |
|
  D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Seyahi, V. Hamuryudan, G. Hatemi, M. Melikoglu, S. Celik, I. Fresko, S. Yurdakul, and H. Yazici Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome Rheumatology, July 1, 2007; 46(7): 1213 - 1214. [Full Text] [PDF]
|
|
|
|
|
|
P. P. Sfikakis, N. Markomichelakis, E. Alpsoy, S. Assaad-Khalil, B. Bodaghi, A. Gul, S. Ohno, N. Pipitone, M. Schirmer, M. Stanford, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations Rheumatology, May 1, 2007; 46(5): 736 - 741. [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15. [Full Text] [PDF]
|
|
|
|
|
|
B Maurer, M Hensel, R Max, C Fiehn, A D Ho, and H M Lorenz Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up Ann Rheum Dis, January 1, 2006; 65(1): 127 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Ribi, R Sztajzel, J Delavelle, and C Chizzolini Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behcet disease J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1733 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv2 - iv14. [Full Text] [PDF]
|
|
|
|
 |
|
 L.M. Al-Otaibi, S.R. Porter, and T.W.J. Poate Behcet's Disease: A Review J. Dent. Res., March 1, 2005; 84(3): 209 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004 Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii2 - ii12. [Full Text] [PDF]
|
|
|
|
|
|
E C Keystone The utility of tumour necrosis factor blockade in orphan diseases Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii79 - ii83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Haugeberg, M Velken, and V Johnsen Successful treatment of genital ulcers with infliximab in Behcet's disease Ann Rheum Dis, June 1, 2004; 63(6): 744 - 745. [Full Text]
|
|
|
|
 |
|
 P. P. Sfikakis, P. H. Kaklamanis, A. Elezoglou, N. Katsilambros, P. G. Theodossiadis, S. Papaefthimiou, and N. Markomichelakis Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades-Behcet Disease Ann Intern Med, March 2, 2004; 140(5): 404 - 406. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Beckman, D. H Pfizenmaier II, and T. W Rooke Clinical pathologic conference: A young man with a thoracoabdominal aneurysm Vascular Medicine, February 1, 2004; 9(1): 70 - 77. [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, M Dougados, P Emery, A Gibofsky, A F Kavenaugh, E C Keystone, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) Ann Rheum Dis, November 1, 2003; 62(90002): ii2 - 9. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
